BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that its Phase 3 ENERGY 3 trial for BMN 401 in children with ENPP1 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE